The metabolic syndrome and risk of chronic kidney disease: Pathophysiology and intervention strategies

Journal of Nutrition and Metabolism

Volumn 2012, Issue , 2012, Pages

  Laguardia, Heather A ^a   Hamm, L Lee ^a   Chen, Jing ^b  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873149586     PISSN: 20900724     EISSN: 20900732     Source Type: Journal    
DOI: 10.1155/2012/652608     Document Type: Review

References (90)

1. Eckel R. H., Alberti K. G. M. M., Grundy S. M., Zimmet P. Z., The metabolic syndrome. The Lancet 2010 375 9710 181 183 2-s2.0-73949115305 10.1016/S0140-6736(09)61794-3
2. Gu D., Reynolds K., Wu X., Chen J., Duan X., Reynolds R. F., Whelton P. K., He J., jhe@tulane.edu Prevalence of the metabolic syndrome and overweight among adults in China. The Lancet 2005 365 9468 1398 1405 10.1016/S0140-6736(05) 66375-1 (Pubitemid 40523734)
3. Ford E. S., Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S. Diabetes Care 2005 28 11 2745 2749 2-s2.0-30544433479 10.2337/diacare.28.11.2745 (Pubitemid 43951170)
4. Coresh J., Selvin E., Stevens L. A., Manzi J., Kusek J. W., Eggers P., Van Lente F., Levey A. S., Prevalence of chronic kidney disease in the United States. Journal of the American Medical Association 2007 298 17 2038 2047 2-s2.0-35848968871 10.1001/jama.298.17.2038 (Pubitemid 350074801)
5. El Nahas A. M., Bello A. K., Chronic kidney disease: the global challenge. The Lancet 2005 365 9456 331 340 2-s2.0-12344250764 10.1016/S0140-6736(05)17789-7 (Pubitemid 40139112)
6. Muntner P., He J., Hamm L., Loria C., Whelton P. K., Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. Journal of the American Society of Nephrology 2002 13 3 745 753 2-s2.0-0036190001 (Pubitemid 34183941)
7. Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C. Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England Journal of Medicine 2004 351 13 1296 1305 2-s2.0-4644221457 10.1056/NEJMoa041031 (Pubitemid 39268908)
8. Kylin E., Hypertension-hyperglycemia-hyperuricemia syndrome. Zentralblatt fur InnereMedizin 1923 44
9. Vague J., La diffférenciacion sexuelle, facteur déterminant des formes de l'obésité La Presse Médicale 1947 30 339 340
10. Haller H., Epidermiology and associated risk factors of hyperlipoproteinemia. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1977 32 8 124 128 2-s2.0-0017774792
11. Singer P., Diagnosis of primary hyperlipoproteinemias. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1977 32 9 129 133 2-s2.0-0017486598
12. Phillips G. B., Sex hormones, risk factors and cardiovascular disease. The American Journal of Medicine 1978 65 1 7 11 2-s2.0-0017852687 (Pubitemid 8389369)
13. Reaven G. M., Role of insulin resistance in human disease. Diabetes 1988 37 12 1595 1607 2-s2.0-0024160877 (Pubitemid 19004941)
14. Lakka H. M., Laaksonen D. E., Lakka T. A., Niskanen L. K., Kumpusalo E., Tuomilehto J., Salonen J. T., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of the American Medical Association 2002 288 21 2709 2716 2-s2.0-0037021505 10.1001/jama.288.21. 2709 (Pubitemid 35403784)
15. Laaksonen D. E., Lakka H. M., Niskanen L. K., Kaplan G. A., Salonen J. T., Lakka T. A., Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. American Journal of Epidemiology 2002 156 11 1070 1077 2-s2.0-0036891935 10.1093/aje/kwf145 (Pubitemid 35396938)
16. Ford E. S., Giles W. H., A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003 26 3 575 581 2-s2.0-0038566287 10.2337/diacare.26.3.575 (Pubitemid 36929310)
17. Mannucci E., Monami M., Cresci B., Pala L., Bardini G., Petracca M. G., Dicembrini I., Pasqua A., Buiatti E., Rotella C. M., National cholesterol education program and international diabetes federation definitions of metabolic syndrome in the prediction of diabetes: results from the firenze-bagno a ripoli study. Diabetes, Obesity and Metabolism 2008 10 5 430 435 2-s2.0-42149157734 10.1111/j.1463-1326.2007.00724.x (Pubitemid 351524290)
18. Nilsson P. M., Engström G., Hedblad B., The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects-a population-based study comparing three different definitions. Diabetic Medicine 2007 24 5 464 472 2-s2.0-34247638064 10.1111/j.1464-5491.2007.02142.x (Pubitemid 46669326)
19. Choi K. M., Kim S. M., Kim Y. E., Choi D. S., Baik S. H., Lee J., International diabetes federation: prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Education Program and International Diabetes Federation definitions in the Korean population. Metabolism: Clinical and Experimental 2007 56 4 552 558 2-s2.0-33947229535 10.1016/j.metabol.2006.12.003 (Pubitemid 46427854)
20. Tong P. C. Y., Kong A. P., So W. Y., Yang X., Ho C. S., Ma R. C., Ozaki R., Chow C. C., Lam C. W., Chan J. C. N., Cockram C. S., The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007 30 5 1206 1211 2-s2.0-34247578634 10.2337/dc06-1484 (Pubitemid 46684649)
21. Athyros V. G., Ganotakis E. S., Elisaf M., Mikhailidis D. P., The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Current Medical Research and Opinion 2005 21 8, article 3094 1157 1159 2-s2.0-23744483066 10.1185/030079905X53333 (Pubitemid 41140717)
22. Alberti K. G. M. M., Eckel R. H., Grundy S. M., Zimmet P. Z., Cleeman J. I., Donato K. A., Fruchart J. C., James W. P. T., Loria C. M., Smith S. C., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009 120 16 1640 1645 2-s2.0-70350245011 10.1161/CIRCULATIONAHA.109.192644
23. Chen J., Muntner P., Hamm L. L., Jones D. W., Batuman V., Fonseca V., Whelton P. K., He J., The metabolic syndrome and chronic kidney disease in U.S. adults. Annals of Internal Medicine 2004 140 3 167 I39 2-s2.0-0742266631
24. Kurella M., Lo J. C., Chertow G. M., Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. Journal of the American Society of Nephrology 2005 16 7 2134 2140 2-s2.0-27444433127 10.1681/ASN.2005010106 (Pubitemid 41716445)
25. Ninomiya T., Kiyohara Y., Kubo M., Yonemoto K., Tanizaki Y., Doi Y., Hirakata H., Iida M., Metabolic syndrome and CKD in a general Japanese population: the hisayama study. American Journal of Kidney Diseases 2006 48 3 383 391 2-s2.0-33747377214 10.1053/j.ajkd.2006.06.003 (Pubitemid 44247252)
26. Tozawa M., Iseki C., Tokashiki K., Chinen S., Kohagura K., Kinjo K., Takishita S., Iseki K., Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertension Research 2007 30 10 937 943 2-s2.0-36248935983 10.1291/hypres.30.937 (Pubitemid 350120971)
27. Natali A., Ferrannini E., Hypertension, insulin resistance, and the metabolic syndrome. Endocrinology and Metabolism Clinics of North America 2004 33 2 417 429 2-s2.0-2542481008 10.1016/j.ecl.2004.03.007 (Pubitemid 38684163)
28. Mathew A. V., Okada S., Sharma K., Obesity related kidney disease. Current Diabetes Reviews 2011 7 1 41 49 2-s2.0-79952748617
29. Le Roith D., Zick Y., Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001 24 3 588 597 2-s2.0-0035091266 (Pubitemid 32198431)
30. Kubo M., Kiyohara Y., Kato I., Iwamoto H., Nakayama K., Hirakata H., Fujishima M., Effect of hyperinsulinemia on renal function in a general Japanese population: the Hisayama study. Kidney International 1999 55 6 2450 2456 2-s2.0-0032992243 10.1046/j.1523-1755.1999.00458.x (Pubitemid 29256500)
31. Manrique C., Lastra G., Gardner M., Sowers J. R., The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Medical Clinics of North America 2009 93 3 569 582 2-s2.0-65449118734 10.1016/j.mcna.2009.02.014
32. Sarafidis P. A., Ruilope L. M., Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. American Journal of Nephrology 2006 26 3 232 244 2-s2.0-33746330410 10.1159/000093632 (Pubitemid 44114394)
33. Bosello O., Zamboni M., Visceral obesity and metabolic syndrome. Obesity Reviews 2000 1 1 47 56 2-s2.0-0034179765
34. Aubert H., Frère C., Aillaud M. F., Morange P. E., Juhan-Vague I., Alessi M. C., Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. Journal of Thrombosis and Haemostasis 2003 1 4 791 797 2-s2.0-0142137406
35. Lamounier-Zepter V., Ehrhart-Bornstein M., Fat tissue metabolism and adrenal steroid secretion. Current Hypertension Reports 2006 8 1 30 34 2-s2.0-33646093249 10.1007/s11906-006-0038-3
36. Goodfriend T. L., Ball D. L., Egan B. M., Campbell W. B., Nithipatikom K., Epoxy-Keto derivative of Linoleic acid stimulates aldosterone secretion. Hypertension 2004 43 2 358 363 2-s2.0-0842333052 10.1161/01.HYP.0000113294. 06704.64 (Pubitemid 38174139)
37. Sowers J. R., Whaley-Connell A., Epstein M., Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Annals of Internal Medicine 2009 150 11 776 783 2-s2.0-66549130863
38. Kambham N., Markowitz G. S., Valeri A. M., Lin J., D'Agati V. D., Obesity-related glomerulopathy: an emerging epidemic. Kidney International 2001 59 4 1498 1509 2-s2.0-0035071325 10.1046/j.1523-1755.2001.0590041498.x (Pubitemid 32281241)
39. Henegar J. R., Bigler S. A., Henegar L. K., Tyagi S. C., Hall J. E., Functional and structural changes in the kidney in the early stages of obesity. Journal of the American Society of Nephrology 2001 12 6 1211 1217 2-s2.0-0035017738 (Pubitemid 32472634)
40. Papafragkaki D. K., Tolis G., Obesity and renal disease: a possible role of leptin. Hormones 2005 4 2 90 95 2-s2.0-33646465587
41. Sowers J. R., Metabolic risk factors and renal disease. Kidney International 2007 71 8 719 720 2-s2.0-34247264495 10.1038/sj.ki.5002006 (Pubitemid 46624014)
42. Cooper S. A., Whaley-Connell A., Habibi J., Wei Y., Lastra G., Manrique C., Stas S., Sowers J. R., Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. American Journal of Physiology 2007 293 4 H2009 H2023 2-s2.0-35148840913 10.1152/ajpheart.00522.2007 (Pubitemid 47605846)
43. Epstein M., Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. The American Journal of Medicine 2006 119 11 912 919 2-s2.0-33750350450 10.1016/j.amjmed.2006.03.038 (Pubitemid 44634312)
44. Nagase M., Yoshida S., Shibata S., Nagase T., Gotoda T., Ando K., Fujita T., Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. Journal of the American Society of Nephrology 2006 17 12 3438 3446 2-s2.0-33845238078 10.1681/ASN.2006080944 (Pubitemid 44865286)
45. Sowers J. R., Hypertension, angiotensin II, and oxidative stress. The New England Journal of Medicine 2002 346 25 1999 2001 2-s2.0-0037142095 10.1056/NEJMe020054 (Pubitemid 34651362)
46. Bomback A. S., Klemmer P. J., Renal injury in extreme obesity: the important role of aldosterone. Kidney International 2008 74 9 1216 2-s2.0-53949115296 10.1038/ki.2008.429
47. Whaley-Connell A., whaleyconnella@health.missouri.edu Habibi J., Wei Y., Gutweiler A., Jellison J., Wiedmeyer C. E., Ferrario C. M., Sowers J. R., Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. American Journal of Physiology 2009 296 5 F1013 F1022 10.1152/ajprenal.90646.2008
48. Krauss R. M., Atherogenicity of triglyceride-rich lipoproteins. American Journal of Cardiology 1998 81 4 13B 17B 2-s2.0-0032567917 10.1016/S0002-9149(98) 00032-0 (Pubitemid 28113940)
49. Krauss R. M., Dense low density lipoproteins and coronary artery disease. American Journal of Cardiology 1995 75 6 53B 57B 2-s2.0-0028954936
50. Ou H. C., Lee W. J., Lee S. D., Huang C. Y., Chiu T. H., Tsai K. L., Hsu W. C., Sheu W. H. H., Ellagic acid protects endothelial cells from oxidized low-density lipoprotein-induced apoptosis by modulating the PI3K/Akt/eNOS pathway. Toxicology and Applied Pharmacology 2010 248 2 134 143 2-s2.0-77956945020 10.1016/j.taap.2010.07.025
51. Ou H. C., Chou F. P., Lin T. M., Yang C. H., Sheu W. H. H., Protective effects of eugenol against oxidized LDL-induced cytotoxicity and adhesion molecule expression in endothelial cells. Food and Chemical Toxicology 2006 44 9 1485 1495 2-s2.0-33745621282 10.1016/j.fct.2006.04.011 (Pubitemid 43994281)
52. Ou H. C., Chou F. P., Lin T. M., Yang C. H., Sheu W. H. H., Protective effects of honokiol against oxidized LDL-induced cytotoxicity and adhesion molecule expression in endothelial cells. Chemico-Biological Interactions 2006 161 1 1 13 2-s2.0-33646107865 10.1016/j.cbi.2006.02.006
53. Manttari M., Tiula E., Alikoski T., Manninen V., Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 1995 26 4 670 675 2-s2.0-0029166463
54. Muntner P., Coresh J., Smith J. C., Eckfeldt J., Klag M. J., Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney International 2000 58 1 293 301 2-s2.0-0033920866 10.1046/j.1523-1755.2000.00165.x (Pubitemid 30429874)
55. Fried L. F., Orchard T. J., Kasiske B. L., Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney International 2001 59 1 260 269 2-s2.0-0035166933 10.1046/j.1523-1755.2001.00487.x (Pubitemid 32055234)
56. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo Jr. J. L., Jones D. W., Materson B. J., Oparil S., Wright Jr. J. T., Roccella E. J., roccelle@nhlbi.nih.gov Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee 2003 Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 42 6 1206 1252 10.1161/01.HYP.0000107251.49515.c2 (Pubitemid 37553153)
57. Ferrannini E., Buzzigoli G., Bonadonna R., Insulin resistance in essential hypertension. The New England Journal of Medicine 1987 317 6 350 357 2-s2.0-0023191508 (Pubitemid 17118813)
58. Steinberg H. O., Brechtel G., Johnson A., Fineberg N., Baron A. D., Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. Journal of Clinical Investigation 1994 94 3 1172 1179 2-s2.0-0028030813
59. Tooke J. E., Hannemann M. M., Adverse endothelial function and the insulin resistance syndrome. Journal of Internal Medicine 2000 247 4 425 431 2-s2.0-0034096785 10.1046/j.1365-2796.2000.00671.x (Pubitemid 30253160)
60. Fujita T., Aldosterone in salt-sensitive hypertension and metabolic syndrome. Journal of Molecular Medicine 2008 86 6 729 734 2-s2.0-43449108835 10.1007/s00109-008-0343-1
61. Tripathy D., Mohanty P., Dhindsa S., Syed T., Ghanim H., Aliada A., Dandona P., Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003 52 12 2882 2887 2-s2.0-0345275811 10.2337/diabetes.52.12.2882 (Pubitemid 37466856)
62. Combs T. P., Berg A. H., Obici S., Scherer P. E., Rossetti L., Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. Journal of Clinical Investigation 2001 108 12 1875 1881 2-s2.0-0035663963 10.1172/JCI200114120 (Pubitemid 34015133)
63. Xu H., Barnes G. T., Yang Q., Tan G., Yang D., Chou C. J., Sole J., Nichols A., Ross J. S., Tartaglia L. A., Chen H., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation 2003 112 12 1821 1830 2-s2.0-9144223683 10.1172/JCI200319451 (Pubitemid 38063705)
64. Azadbakht L., Mirmiran P., Esmaillzadeh A., Azizi T., Azizi F., Beneficial effects of a dietary approaches to stop hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005 28 12 2823 2831 2-s2.0-33644833225 10.2337/diacare.28.12.2823 (Pubitemid 43942910)
65. Liu S., Choi H. K., Ford E., Song Y., Klevak A., Buring J. E., Manson J. E., A prospective study of dairy intake and the risk of type 2 diabetes in women. Diabetes Care 2006 29 7 1579 1584 2-s2.0-33746465465 10.2337/dc06-0256 (Pubitemid 44127584)
66. Choi H. K., Willett W. C., Stampfer M. J., Rimm E., Hu F. B., Dairy consumption and risk of type 2 diabetes mellitus in men: a prospective study. Archives of Internal Medicine 2005 165 9 997 1003 2-s2.0-18344374457 10.1001/archinte.165.9.997 (Pubitemid 40638119)
67. Pereira M. A., Jacobs D. R., Van Horn L., Slattery M. L., Kartashov A. I., Ludwig D. S., Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA study. Journal of the American Medical Association 2002 287 16 2081 2089 2-s2.0-0037165703 (Pubitemid 34437343)
68. Giugliano D., Ceriello A., Esposito K., Are there specific treatments for the metabolic syndrome? The American Journal of Clinical Nutrition 2008 87 1 8 11 2-s2.0-38149095747
69. Hoffmann I. S., Cubeddu L. X., Increased blood pressure reactivity to dietary salt in patients with the metabolic syndrome. Journal of Human Hypertension 2007 21 6 438 444 2-s2.0-34249305191 10.1038/sj.jhh.1002153 (Pubitemid 46813593)
70. Chen J., jchen@tulane.edu Gu D., Huang J., Rao D. C., Jaquish C. E., Hixson J. E., Chen C.-S., Chen J., Lu F., Hu D., Rice T., Kelly T. N., Hamm L. L., Whelton P. K., He J., Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. The Lancet 2009 373 9666 829 835 10.1016/S0140-6736(09)60144-6
71. Orchard T. J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., Fowler S., The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program randomized trial. Annals of Internal Medicine 2005 142 8 611 619 2-s2.0-17144389303 (Pubitemid 40529957)
72. Diabetes Prevention Program Research Group, 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. The Lancet 2009 374 9702 1677 1686 2-s2.0-70449517253 10.1016/S0140-6736(09) 61457-4
73. Vitale C., Mercuro G., Cornoldi A., Fini M., Volterrani M., Rosano G. M. C., Metformin improves endothelial function in patients with metabolic syndrome. Journal of Internal Medicine 2005 258 3 250 256 2-s2.0-24144488274 10.1111/j.1365-2796.2005.01531.x (Pubitemid 41243057)
74. Salpeter S. R., Greyber E., Pasternak G. A., Salpeter E. E., Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Archives of Internal Medicine 2003 163 21 2594 2602 2-s2.0-0344420380 10.1001/archinte.163.21.2594 (Pubitemid 37464417)
75. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein H. C., Yusuf S., Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet 2006 368 9541 1096 1105
76. Szapary P., Bloedon L., Samaha F. F., The effects of pioglitazone on lipoproteins in non-diabetics with metabolic syndrome: results from a randomized controlled trial. Proceedings of the 65th Scientific Sessions of the American Diabetes Association: Program and Abstracts June 2005 San Diego, Calif, USA
77. Tan M. H., Deeg A., Goldberg R. B., Comparison of pioglitazone and rosiglitazone on atherogenic index of plasma in patients with type 2 diabetes and dyslipidemia. Proceedings of the 65th Scientific Sessions of the American Diabetes Association: Program and Abstracts June 2005 San Diego, Calif, USA
78. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Journal of the American Medical Association 2001 285 19 2486 2497 2-s2.0-0035897696
79. Deedwania P., Barter P., Carmena R., Fruchart J. C., Grundy S. M., Haffner S., Kastelein J. J., LaRosa J. C., Schachner H., Shepherd J., Waters D. D., Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study. The Lancet 2006 368 9539 919 928 2-s2.0-33748303084 10.1016/S0140- 6736(06)69292-1 (Pubitemid 44331360)
80. Ballantyne C. M., Olsson A. G., Cook T. J., Mercuri M. F., Pedersen T. R., Kjekshus J., Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001 104 25 3046 3051 2-s2.0-0035910051 (Pubitemid 34014055)
81. Ballantyne C. M., Stein E. A., Paoletti R., Southworth H., Blasetto J. W., Barter P., Rader D. J., Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. American Journal of Cardiology 2003 91 5 25 27 2-s2.0-0037422068 10.1016/S0002-9149(03)00006-7 (Pubitemid 36332152)
82. Takemoto M., Liao J. K., Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 11 1712 1719 2-s2.0-0035572718 (Pubitemid 34219772)
83. Robinson J. G., Ballantyne C. M., Grundy S. M., Hsueh W. A., Parving H. H., Rosen J. B., Adewale A. J., Polis A. B., Tomassini J. E., Tershakovec A. M., Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET Study). American Journal of Cardiology 2009 103 12 1694 1702 2-s2.0-67649397411 10.1016/j.amjcard.2009.05.003
84. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., Grassi G., Heagerty A. M., Kjeldsen S. E., Laurent S., Narkiewicz K., Ruilope L., Rynkiewicz A., Schmieder R. E., Boudier H. A. J. S., Zanchetti A., 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2007 25 6 1105 1187 2-s2.0-34250350040 10.1097/HJH.0b013e3281fc975a (Pubitemid 46924065)
85. Elliott W. J., Meyer P. M., Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet 2007 369 9557 201 207 2-s2.0-33846294746 10.1016/S0140-6736(07)60108-1 (Pubitemid 46111014)
86. Messerli F. H., Grossman E., Leonetti G., Antihypertensive therapy and new onset diabetes. Journal of Hypertension 2004 22 10 1845 1847 2-s2.0-5044223690 10.1097/00004872-200410000-00001 (Pubitemid 39336662)
87. Wright J. T., Harris-Haywood S., Pressel S., Barzilay J., Baimbridge C., Bareis C. J., Basile J. N., Black H. R., Dart R., Gupta A. K., Hamilton B. P., Einhorn P. T., Julian Haywood L., Jafri S. Z. A., Louis G. T., Whelton P. K., Scott C. L., Simmons D. L., Stanford C., Davis B. R., Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2008 168 2 207 217 2-s2.0-38749150577 10.1001/archinternmed.2007.66 (Pubitemid 351185889)
88. Black H. R., Davis B., Barzilay J., Nwachuku C., Baimbridge C., Marginean H., Wright J. T., Basile J., Wong N. D., Whelton P., Dart R. A., Thadani U., Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008 31 2 353 360 2-s2.0-38949084591 10.2337/dc07-1452 (Pubitemid 351213350)
89. Strasser B., Siebert U., Schobersberger W., Resistance training in the treatment of the metabolic syndrome: a systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Medicine 2010 40 5 397 415 2-s2.0-77951871641 10.2165/11531380-000000000-00000
90. Lee W. J., Huang M. T., Wang W., Lin C. M., Chen T. C., Lai I. R., Effects of obesity surgery on the metabolic syndrome. Archives of Surgery 2004 139 10 1088 1092 2-s2.0-5444247120 10.1001/archsurg.139.10.1088 (Pubitemid 39362275)